secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001437749-25-030110
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 5.02, 9.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025
--------------------------------------------------------------------------------

- Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.
- Current CEO Michael Brigham to become Special Advisor for at least two months and remain on Board.
- Base salary of $450,000, annual bonus up to $400,000, $100,000 signing bonus.
- Received inducement stock option for 76,673 shares at $5.90; second grant for up to 85,000 shares.
- Options vest over three years; options granted Sep 16, 2025 have 10-year term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774925030110/0001437749-25-030110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774925030110/iccc20250827_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-030110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer